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Background: Branched chain amino acid (BCAA) supplementation is a recently identified strategy to promote
longevity in mice. A proteomic approach was used to identify proteins which are differentially expressed in the sera
of mice following supplementation with selected branched chain amino acid enriched mixture (BCAAem).
Findings: 12 male mice (C57Bl6, 9 months-old) were randomly assigned to unsupplemented (Control, n = 6) and
supplemented (BCAA, n = 6, 0.1 mg/gr/day in drink water for 4 weeks). At the end of treatment total plasma
samples from Control and BCAAem mice were separated by two-dimensional gel electrophoresis (2-DE). After
staining, the gels were imaged and differential protein expression patterns were interrogated using image analysis
software. Spots showing a different expression level were identified through a comparison with 2D maps found in
databases officially recognized (ExPASy).
Master gels of Control and BCAA mice exhibited slightly different 2-DE patterns as only 10 spots out of 500
appeared differentially expressed: 8 were upregulated (corresponding to Apolipoprotein A-I (APOA1), Complement
factor B, Complement C3, Immunoglobulin light chain) and 2 appeared downregulated (Alpha-1-antitrypsin and
unknown).
Conclusions: Supplementation with BCAAem in mice results in a slight perturbation of the host serum proteome.
Of particular interest is the increased Apolipoprotein A-I (APOAI) following treatment.
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In ageing common metabolic, inflammatory, cardiovas-
cular and neurodegenerative diseases, ultimately reduce
healthspan and lifespan.
Regardless of the mechanism, a common feature of
aging-related diseases is the involvement of metabolic sys-
tems in general, and the mitochondria in particular [1].
We have recently demonstrated that supplementation of
aged mice with a branched-chain amino acid-enriched
mixture (BCAAem) promotes mitochondrial biogenesis
and function, with a reduced radical oxygen species (ROS)
production and extension of mean survival [2]. All the
BCAAem-mediated effects appeared to be considerably
enhanced by combined resistance exercise training and
strongly attenuated in endothelial nitric oxide synthase
null-mutant mice (eNOS−/−) or after rapamycin, an* Correspondence: gdantona@unipv.it
1Department of Molecular Medicine, University of Pavia, Pavia, Italy
2LUSAMMR, Laboratory for Motor Activities in Rare Diseases, Sport Medicine
Centre Voghera, Voghera, Italy
© 2013 Brocca et al.; licensee BioMed Central
Commons Attribution License (http://creativec
reproduction in any medium, provided the orinhibitor of mammalian target of rapamycin (mTOR)
pathway. Although a direct metabolic effect of BCAAem
on skeletal muscles contributes to the overall change in
mitochondrial biogenesis and function and antioxidant ac-
tivity [2], an indirect tissue effect mediated or sustained by
circulating factors may contribute to the observed effects
on survival or, simply, may represent footprint biomarkers
of the nutritional strategy. This concern might also be
considered in order to clarify the mechanisms underlying
the known beneficial effect of BCAA supplementation be-
fore and after exercise mainly consisting in decreased
exercise-induced muscle damage and promoted muscle
protein synthesis [3]. Indeed initial reports highlight the
effects of BCAA enriched mixtures supplementation on
the pattern of circulating factors such as cytokines [4] and
hormones (i.e. GH) following exercise in humans [5].
Here we used plasma proteomics to investigate
whether dietary supplementation with BCAAem would
impact on the plasma protein profile thus defining aLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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adult sedentary mice.
Methods
12 male mice (F2 Hybrid B6.129S2 obtained from cross-
ing C57BL/6 J and 129S1/SvImJ mice, 9 month at the
beginning of treatment) (The Jackson Laboratory),
housed one per cage and maintained at 20°C, 12 h/
12 h day/night cycles, were treated according to the EU
guidelines and with the approval of the Institutional Eth-
ical Committee. Animals were given unrestricted access
to a standard diet (4.3 kcal% fat, 18.8 kcal% protein,
76.9 kcal% carbohydrate, Laboratorio Dottori Piccioni)
and were randomly assigned to two groups: unsupple-
mented (Ct, n = 6) and supplemented (BCAA, 0.1 gr/kg/
day in drinking water, n = 6). Consumption of food and
water was monitored along the treatment and appeared
not statistical different between groups. (Ct, 3.1 ± 0.01 g/
day and 6.5 ± 1.0 ml/day, n = 6; BCAA, 3.3 ± 0.03 g/day
and 6.0 ± 1.2 ml/day, n = 6 respectively p > 0.05). The
amino acid supplement BCAAem (composition: 31.25%
leucine, 16.25% lysine, 15.52% valine, 15.52% isoleucine,
8.75% threonine, 3.75% cysteine, 3.75% histidine, 2.6%
phenylalanine, 1.25% methionine, 0.75% tyrosine, 0.5%
tryptophan) was administered with a daily dose of 0.1
gr/kg body weight dissolved in tap water on basis of the
previously monitored daily drinking (average drinking
6.65 ± 1.5 ml/day, n = 12).
At the end of treatment in the late morning and after
at least 4 h fasting, mice were weighted (Ct, 30 ± 1 g
n = 6; BCAA 29 ± 1.2 g n = 6, p > 0.05) and a blood sam-
ple (around 400 μL) was withdrawn from the retro or-
bital sinus of each mouse under slight ether anesthesia.
The samples were centrifuged at 8000 g for 15 min in
order to separate the serum fractions which were frozen
in liquid nitrogen and maintained at −80°C for subse-
quent analysis.
Two-dimensional electrophoresis analysis
Protein concentration of each sample were determine
using the DC Protein Assay (by Bio-Rad), a colorimetric
assay based on the method of Lowry [6].
100 μg of protein for each sample (Ct and BCAA)
were precipitated in 8 volumes of acetone and then
resuspended in a 2D lysis buffer (8 M urea, 2 M thio-
urea, 4% Chaps, 65 mM DTT and 40 mM Tris base). All
Ct samples were combined to create a Ct sample mix
and the same was done for samples BCAA. 150 μg of
protein from each sample mix were used to perform the
2D-electrophoresis analysis. Isoelectrofocusing was car-
ried out with the IPGphor system (Ettan IPGphor
isoelectric focusing system, GE Healtcare) using IPG
gel strips pH 3–11 NL, 13 cm long. Gel strips were
rehydrated for 14 hours, at 30 V and 20°C, in 250 μl ofreswelling buffer (8 M urea, 2 M thiourea, 2% Chaps,
0.1% tergitol NP7, Sigma) and focused at 20000 V/h at
20°C. After they were incubated 10 min in equilibration
buffer (50 mM Tris pH 6.8, 6 M urea, 30% glycerol, 2%
SDS, 3% iodoacetamide) before being applied on 15%
SDS-Page gel without staking gel. The separation of
protein spots was performed at 80 V for 17 h at room
temperature.
After having been fixed for 2 hours in a fix solution
(40% ethanol, 10% acetic acid), the 2D gels were stained
with fluorescent staining (Flamingo™ fluorescent gel
stain, Bio-Rad) for 3 hours and destained in 0.1% Tween
20 solution for 10 min.
For each mix samples we obtained three different gels
visualized by Typhoon laser scanner (GE Healtcare) and
then analyzed with Platinum software (GE Healtcare).
The software compared BCAA with Ct group by
choosing a master gel used for the automatic matching
of spots in other 2D-gels. At the end the analysis
we obtained for each spot the normalized volume
representing the protein amount. Then we averaged the
volumes of the corresponding spots in three replicate
gels getting spots that statistically changed (p < 0.05).
Finally we compared our proteomic maps with those
published on specific databases (ExPASy) in order to
identify differentially expressed spots.
Statistical analysis
Statistical analysis was performed with GraphPad
PrismW 5.02 software (GraphPad Software, San Diego,
CA). Results are expressed as means ± standard devi-
ation of the mean (SD). Statistical significance was
calculated using unpaired Student’s t-test. Statistical
significance was set to p < 0.05.
Results
Representative 2-DE gels for Ct and BCAA are reported
in Figure 1 and identity and fold changes of identified
plasma proteins are reported in Table 1. By matching 2D
gels from Ct and BCAA around 500 common spots were
analyzed whereas only 10 spots appeared differentially
expressed. Among them 8 appeared upregulated and
identified as Apolipoprotein A-I (APOAI), Complement
factor B, Complement C3, Immunoglobulin light chain
and 2 appeared downregulated identified as Alpha-1
-antitrypsin and unknown.
Conclusions
As far as we know this is the first available proteomic
analysis of the plasma proteins expression profile after
BCAA enriched mixture supplementation in mice.
Results showed that 1) a limited number of proteins
changed expression in the plasma of supplemented in
comparison with control unsupplemented animals; 2)
Figure 1 Example of typical 2-DE gel image of plasma proteins extract. Left, Changed spots circled and numbered. Right, Identified proteins
and fold changes. APO A-I, Apolipoprotein A-I; CFAB, Complement Factor B; IGCL, Immunoglobulin light chain; A1AT, Alpha-1-antitrypsin.
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and were identified as Apolipoprotein A-I.
In our study the oral supplementation with BCAAem
for four weeks was associated with a minor change of
the 2-DE pattern profile as only 10 spots out of 500
appeared differentially expressed between supplemented
and unsupplemented mice. In particular the upregulated
spots were identified as Apolipoprotein A-I, Comple-
ment factor B, Complement C3, Immunoglobulin light
chain whereas the downregulated spots were Alpha-1
-antitrypsin and an unidentified protein.
Apolipoprotein A-I is a major protein component of
high density lipoprotein (HDL) in the plasma and partic-
ipates to the reverse cholesterol transport (RCT) from
tissues to liver where it can be excreted directly into the
bile or metabolized into bile salts before excretion [7,8].
Lipid-poor Apo A-I/HDL are known to act as acceptorsTable 1 Identification of changed plasma protein following B
Protein name Protein name Accession nu
1 Apolipoprotein A-I APOAI Q00623
2 Apolipoprotein A-I APOAI Q00623
3 Apolipoprotein A-I APOAI Q00623
4 Apolipoprotein A-I APOAI Q00623
5 Complement factor B CFAB P04186
6 Complement C3 CO3 P01027
7 Complement C3 CO3 P01027
8 Immunoglobulin light chain IGCL Q925S9
9 Alpha-1-antitrypsin A1AT P07758
10 Unknowfor cellular lipids, and lipid efflux from cells can be me-
diated via cell surface proteins (ABCA1, ABCG1 and
SR-BI) [9]. RCT represents the foremost mechanism
underlying the anti-atherogenic effects of Apo A-I. Apart
from its participation to the RTC HDL/Apo A-I might
exert their anti-atherogenic effects through several other
mechanisms. For example, it has been demonstrated that
HDL/Apo A-I have anti-inflammatory activity [10] being
capable to reduce oxidized lipids and its inflammatory
effects [11,12].
In experimental studies using atherosclerosis-susceptible
mice (inbred C57BL/6, used in the present study), it was
observed that transgenic overexpression of human ApoA-
I significantly protected from development of early athero-
sclerotic lesions [13]. Similarly, overexpression of human
ApoA-I in apoE-deficient transgenic mice suppressed early
atherosclerotic lesions [14]. Furthermore, knocking outCAAem supplementation by ExPASy
mber Fold change Physiological function
2.70 Partecipates in RTC from tissues to liver
2.10 Partecipates in RTC from tissues to liver
1.80 Partecipates in RTC from tissues to liver
1.38 Partecipates in RTC from tissues to liver
1.54 Is part of the alternate pathway of the
complement system
1.19 Plays a central role in the activation of the
complement system
2.20 Plays a central role in the activation of the
complement system
2.24
- 2.03 Inhibitor of serine proteases
Acute phase response
−4.97
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ment in several animal models (i.e. the human apoB-
transgenic female mice; the LDL receptor-deficient; the
LDL receptor/apoE-deficient mice) [15,16].
Taking into account that increasing ApoA-I produc-
tion is now considered a target for coronary heart dis-
ease (CHD) risk reduction, beside pharmacological
agents, several studies have focused on nutritional
compounds affecting serum apoA-I concentration. For
instance it has been found that, saturated fatty acids
(SAFAs) and cis-monounsaturated fatty acids (cis-
MUFAs), lecithin (consisting of three phospholipids;
phosphatidylcholine (PC), phosphatidylethanolamine
(PE), and phosphatidylinositol (PI)) and moderate
amounts of ethanol [17] increase serum ApoA-I concen-
trations [18] but the mechanisms underlying these
changes remain to be fully elucidated. Beside the energy-
delivering nutrients diverse micronutrients, such as min-
erals (e.g. zinc, magnesium, and vanadate) and vitamins
(e.g., vitamin C, vitamin D, vitamin E, and vitamin A,
vitamin B3), might also enhance ApoA-I synthesis
[19,20]. Anyhow whether these findings also hold for the
in vivo situation remains to be confirmed [21]. In our
study we describe, for the first time, an increased Apo
A-I plasma concentration following BCAA enriched
mixture supplementation in the wild type mouse. The
likely role of essential amino acids in Apo A-I synthesis
deserves future investigations.
In this study, we observed an increase in Complement
C3 (CO3) and Complement Factor B (CFB) plasma pro-
teins. CO3 plays a central role in the complement sys-
tem activation. Its processing by C3 convertase is the
central reaction in both classical and alternative com-
plement pathways. After activation C3b can bind
covalently via its reactive thioester to cell surface carbo-
hydrates or immune aggregates [22]. Elevated C3 con-
centrations were associated with increased risk of
impaired insulin sensitivity, insulin resistance, abdom-
inal obesity and low HDL cholesterol compared to low
C3 concentrations. Increased CHD risk conferred by
elevated C3 concentrations is further accentuated
among high dietary fat consumers and monounsatu-
rated fat [23].
CFB is a fundamental component of the alternative
complement pathway. Following the activation of alter-
native pathway factor B is cleaved by complement factor
D into 2 fragments of different molecular weight, Ba
(noncatalytic chain) and Bb (catalytic chain). Both of
these fragments express a variety of biological functions.
In particular Bb is a serine protease that combines with
complement factor 3b to generate the C3 or C5
convertase. Bb is involved in the proliferation of
preactivated B lymphocytes, while Ba inhibits their
proliferation.Factor B hyperconsumption and increased catabolism,
concomitant with factor B fragment production, occurs
in a wide variety of diseases, including gram-negative
sepsis, autoimmune diseases and burns [24] whereas
very few data are reported on the effects of dietary sup-
plementations on CFB plasma levels [25,26]. An in-
creased CFB concentration could enhance the immune
response of the alternative pathway, by providing more
factors B to be spun to generate more C3-convertase
thus increasing the amount of its secondary reactions
described above.
Although the significance of the observed changes and
the underlying mechanisms deserve future investiga-
tions, the evidence of a contemporaneous increase of
Apo A-I and Complement proteins allow us to speculate
about a protective role of increased HDL following sup-
plementation. In fact, in vitro studies indicate that HDL
blocks the assembly of the terminal complement attack
complex on endothelial cells [27]. Indeed the observed
decrease in Alpha-1-antitrypsin (A1AT) a serine prote-
ases inhibitor related to acute phase response [28] is
probably a sign of the improvement in HDL protective
capabilities sustained by BCAAem supplementation.
Finally in our analysis we found an increase in Im-
munoglobulin light chain (IgLC) levels. Studies have
shown that IgLC can bind to mast cells facilitating their
activation [29] thus contributing to the development of
inflammatory disease. Furthermore excess of IgLC may
modulate the apoptotic cell death of neutrophils thus
contributing to increased susceptibility to bacterial infec-
tions in presence of renal failure [30,31]. Considering
that only one spot identified as IgLC appeared to be in-
creased following supplementation and that no signs of
renal dysfunction have been detected following long-
term BCAAem supplementation [32], quantitative and
qualitative significance of the change observed in our
study remains to be elucidated.
Limitations of the study
Our study has limitations. First our results are to be
considered preliminary as only an age, 9 months corre-
sponding to adulthood in mice, has been analyzed. Sec-
ond, the identification of proteins was based on available
proteome database in the mouse (ExPASy) and not on
mass spectrometry. Anyhow we reckon that the latter
limitation is not a major bias as, to date, available data-
bases on proteome of mouse plasma are highly reliable.
Furthermore a direct translation of results to human be-
ings in unlikely as the daily dose usually adopted in mice
(0.1gr/gr/day) are around ten fold those suggested in
humans (0.1gr/kg/day), as in mice dose correction is
made for the higher basal metabolism [33].
Notwithstanding these limitations, results from our
study opens up a new avenue of research, aimed to
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markers to the effects of BCAA enriched mixtures sup-
plementations in mammals.
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